Management of Agressive Pituitary Tumors
Andrew Lin, MD
Neuro-Oncologist & Neurologist
Memorial Sloak Kettering Cancer Center
During the conversation I will be:
1) Defining aggressive pituitary tumors.
2) Reviewing the current treatment options for aggressive pituitary tumors.
3) Discussing experimental treatment options including a phase II trial investigating the activity of the immunotherapies nivolumab and ipilimumab.
Dr. Lin is a neuro-oncologist at Memorial Sloan Kettering Cancer Center (MSK) and a member of the Multidisciplinary Pituitary & Skull Base Tumor Center. In collaboration with his colleagues in endocrine, neurosurgery, and radiation oncology, he treat patients with aggressive pituitary tumors, who are resistant to conventional treatments (i.e. surgery and radiation), with chemotherapy. Dr. Lin and the team at Memorial Sloan Kettering have published several research articles on pituitary tumors and opened several clinical trials.